Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PTGS2 | P35354 | 1/20 | 0.40 |
| ▸ | PKM | P14618 | 3/20 | 0.37 |
| ▸ | NLRP3 | Q96P20 | 2/20 | 0.37 |
| ▸ | CYP19A1 | P11511 | 3/20 | 0.37 |
| ▸ | USP2 | O75604 | 1/20 | 0.36 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.36 |
| ▸ | UBE2D3 | P61077 | 1/20 | 0.34 |
| ▸ | FNTA | P49354 | 1/20 | 0.34 |
| ▸ | FNTB | P49356 | 1/20 | 0.34 |
| ▸ | PGGT1B | P53609 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29587762 | 1.00 | PTGS2 (0.40) | PTGS2PKMNLRP3CYP19A1USP2 | |
| Vernoflexin SCHEMBL31570936 | 0.88 | NLRP3 (0.35) | PTGS2PKMNLRP3CYP19A1 | |
| Isozaluzanin C SCHEMBL24453721 | 0.78 | PKM (0.40) | PTGS2PKMNLRP3CYP19A1CYP3A4 | |
| Isozaluzanin C SCHEMBL17214374 | 0.78 | PKM (0.40) | PTGS2PKMNLRP3CYP19A1CYP3A4 | |
| SCHEMBL31395402 | 0.77 | NLRP3 (0.54) | PKMNLRP3UBE2D3 | |
| Dehydrocostuslactone SCHEMBL936050 | 0.73 | CYP19A1 (0.46) | PTGS2PKMNLRP3CYP19A1CYP3A4 | |
| Dehydrocostuslactone SCHEMBL699070 | 0.73 | CYP19A1 (0.46) | PTGS2PKMNLRP3CYP19A1CYP3A4 | |
| Dehydrocostuslactone SCHEMBL31029489 | 0.73 | CYP19A1 (0.46) | PTGS2PKMNLRP3CYP19A1CYP3A4 | |
| Vernoflexuoside SCHEMBL1644624 | 0.73 | PTPN1 (0.38) | — | |
| SCHEMBL22305507 | 0.69 | PKM (0.41) | PTGS2PKMNLRP3CYP19A1CYP3A4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20220160804-A1 | USE OF LAURUS NOBILIS EXTRACT FRACTIONS TO PROTECT AGAINST AIR POLLUTION RELATED DISEASES | DSM IP ASSETS B.V. (NL) | 2022-05-26 | — | — | US | disclosed |
| WO-2020156908-A1 | USE OF LAURUS NOBILIS EXTRACT FRACTIONS TO PROTECT AGAINST AIR POLLUTION RELATED DISEASES | DSM IP ASSETS B.V. (NL) | 2020-08-06 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220160804-A1 | USE OF LAURUS NOBILIS EXTRACT FRACTIONS TO PROTECT AGAINST AIR POLLUTION RELATED DISEASES | NOS2, NOS1, NOS3 | PTGS2 85/4885PKM 2705/4885NLRP3 404/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.